Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$47.3 - $70.6 $66,220 - $98,839
-1,400 Reduced 77.78%
400 $19,000
Q2 2023

Aug 14, 2023

SELL
$48.26 - $78.59 $82,042 - $133,603
-1,700 Reduced 48.57%
1,800 $122,000
Q1 2023

May 15, 2023

BUY
$46.97 - $58.27 $164,395 - $203,945
3,500 New
3,500 $169,000
Q4 2021

Feb 14, 2022

SELL
$42.11 - $73.26 $84,220 - $146,520
-2,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $96,400 - $157,780
2,000 New
2,000 $142,000
Q2 2021

Aug 16, 2021

SELL
$21.63 - $57.65 $19,467 - $51,885
-900 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$11.0 - $28.24 $9,900 - $25,416
900 New
900 $23,000
Q2 2020

Aug 14, 2020

SELL
$9.56 - $12.51 $373,796 - $489,141
-39,100 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$7.54 - $15.77 $1.3 Million - $2.73 Million
-172,900 Reduced 81.56%
39,100 $418,000
Q4 2019

Feb 14, 2020

BUY
$7.48 - $17.01 $1.59 Million - $3.61 Million
212,000 New
212,000 $3.36 Million
Q2 2019

Aug 14, 2019

SELL
$8.85 - $12.49 $13,275 - $18,735
-1,500 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$10.32 - $14.49 $1.38 Million - $1.94 Million
-133,700 Reduced 98.89%
1,500 $18,000
Q4 2018

Feb 14, 2019

BUY
$8.73 - $13.74 $935,856 - $1.47 Million
107,200 Added 382.86%
135,200 $1.39 Million
Q3 2018

Nov 14, 2018

SELL
$12.7 - $15.79 $290,830 - $361,591
-22,900 Reduced 44.99%
28,000 $366,000
Q2 2018

Aug 14, 2018

BUY
$10.99 - $44.21 $559,391 - $2.25 Million
50,900 New
50,900 $742,000
Q1 2018

May 15, 2018

SELL
$27.95 - $45.04 $204,035 - $328,792
-7,300 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$35.44 - $63.76 $258,711 - $465,448
7,300
7,300 $272,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $678M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.